Radiopharmaceuticals: When and how to use them to treat metastatic bone pain

Journal of Supportive Oncology

Volumn 9, Issue 6, 2011, Pages 197-205

  Paes, Fabio M ^a   Ernani, Vinicius ^a   Hosein, Peter ^a   Serafini, Aldo N ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; DOXORUBICIN; ESTRAMUSTINE; ETIDRONIC ACID RE 186; KETOCONAZOLE; LEXIDRONAM SAMARIUM SM 153; PACLITAXEL; PAMIDRONIC ACID; RADIOPHARMACEUTICAL AGENT; STRONTIUM 89; VINBLASTINE; ZOLEDRONIC ACID;

BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; PLASMA CLEARANCE; PROSTATE CANCER; RADIATION DOSE; RADIATION HAZARD; RADIATION SAFETY; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT DURATION;

BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; PAIN; PATIENT SELECTION; RADIOPHARMACEUTICALS;

EID: 83455244321     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2011.06.004     Document Type: Review

References (69)

1. Paes F.M., Serafini A.N. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010, 40(2):89-104.
2. Lam M.G., de Klerk J.M., van Rijk P.P., et al. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med Chem 2007, 7(4):381-397.
3. Clines G.A., Guise T.A. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008, 10:e7.
4. Clezardin P., Teti A. Bone metastasis: pathogenesis and therapeutic implications. Clin Exp Metastasis 2007, 24(8):599-608.
5. Saarto T., Janes R., Tenhunen M., et al. Palliative radiotherapy in the treatment of skeletal metastases. Eur J Pain 2002, 6(5):323-330.
6. Hillegonds D.J., Franklin S., Shelton D.K., et al. The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc 2007, 99(7):785-794.
7. Serafini A.N. Therapy of metastatic bone pain. J Nucl Med 2001, 42(6):895-906.
8. Chow E., Wu J.S., Hoskin P., et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 2002, 64(3):275-280.
9. Tong D., Gillick L., Hendrickson F.R. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer 1982, 50(5):893-899.
10. Poulter C.A., Cosmatos D., Rubin P., et al. A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. Int J Radiat Oncol Biol Phys 1992, 23(1):207-214.
11. Dy S.M., Asch S.M., Naeim A., et al. Evidence-based standards for cancer pain management. J Clin Oncol 2008, 26(23):3879-3885.
12. Hobbs R.F., McNutt T., Baechler S., et al. A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. Int J Radiat Oncol Biol Phys 2011, 80(4):1256-1262.
13. Finlay I.G., Mason M.D., Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005, 6(6):392-400.
14. Pandit-Taskar N., Batraki M., Divgi C.R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004, 45(8):1358-1365.
15. Lambert B., de Klerk J.M. Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun 2006, 27(3):223-229.
16. Lewington V.J. Cancer therapy using bone-seeking isotopes. Phys Med Biol 1996, 41(10):2027-2042.
17. Ferro-Flores G., Arteaga de Murphy C. Pharmacokinetics and dosimetry of (188)Re-pharmaceuticals. Adv Drug Deliv Rev 2008, 60(12):1389-1401.
18. Kavakli K., Aydogdu S., Taner M., et al. Radioisotope synovectomy with rhenium186 in haemophilic synovitis for elbows, ankles and shoulders. Haemophilia 2008, 14(3):518-523.
19. Bucerius J., Wallny T., Brackmann H.H., et al. Rhenium-186 hydroxyethylidenediphosphonate (186Re HEDP) for the treatment of hemophilic arthropathy: first results. Clin J Pain 2007, 23(7):612-618.
20. Döbert N., Martin H., Kranert W.T., et al. Re-186 HEDP conditioning therapy in patients with advanced acute lymphoblastic leukemia before allogeneic bone marrow transplantation. Clin Nucl Med 2003, 28(9):738-742.
21. Rodriguez V., Anderson P.M., Litzow M.R., et al. Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. Leuk Lymphoma 2006, 47(8):1583-1592.
22. Rodriguez V., Erlandson L., Arndt C.A., et al. Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatr Transplant 2005, 9(1):122-126.
23. Luo T.Y., Tang I.C., Wu Y.L., et al. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Nucl Med Biol 2009, 36(1):81-88.
24. Casacó A., López G., García I., et al. Phase I single-dose study of intracavitary-administered nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther 2008, 7(3):333-339.
25. Torres-Garcia E., Ferro-Flores G., Arteaga de Murphy C., et al. Biokinetics and dosimetry of 188Re-anti-CD20 in patients with non-Hodgkin's lymphoma: preliminary experience. Arch Med Res 2008, 39(1):100-109.
26. Fani M., Xanthopoulos S., Archimandritis S.C., et al. Biodistribution and scintigraphic studies of 153Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy. Anticancer Res 2003, 23(3A):2195-2199.
27. Bodei L., Lam M., Chiesa C., et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2008, 35(10):1934-1940.
28. Silberstein E.B., Taylor A.T. EANM procedure guidelines for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 2003, 30(3):BP7-BP11.
29. Kraeber-Bodere F., Campion L., Rousseau C., et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 2000, 27(10):1487-1493.
30. Gkialas I., Iordanidou L., Galanakis I., et al. The use of radioisotopes for palliation of metastatic bone pain. J BUON 2008, 13(2):177-183.
31. Tu S.M., Kim J., Pagliaro L.C., et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 2005, 23(31):7904-7910.
32. Zafeirakis A. Can response to palliative treatment with radiopharmaceuticals be further enhanced?. Hell J Nucl Med 2009, 12(2):151-157.
33. Lin A., Ray M.E. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev 2006, 25(4):669-675.
34. Farhanghi M., Holmes R.A., Volkert W.A., et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992, 33(8):1451-1458.
35. De Klerk J.M., Zonnenberg B.A., Blijham G.H., et al. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP. Anticancer Res 1997, 17(3B):1773-1777.
36. Collins C., Eary J.F., Donaldson G., et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993, 34(11):1839-1844.
37. Taylor A.J. Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med 1994, 35(12):2054.
38. Blake G.M., Zivanovic M.A., Blaquiere R.M., et al. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 1988, 29(4):549-557.
39. Dafermou A., Colamussi P., Giganti M., et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001, 28(7):788-798.
40. Windsor P.M. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Clin Oncol (R Coll Radiol) 2001, 13(3):219-227.
41. Eary J.F., Collins C., Stabin M., et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993, 34(7):1031-1036.
42. Robinson R.G., Preston D.F., Schiefelbein M., et al. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995, 274(5):420-424.
43. Sciuto R., Tofani A., Festa A., et al. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy. Clin Ther 1998, 149(921):43-47.
44. Tu S.M., Millikan R.E., Mengistu B., et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001, 357(9253):336-341.
45. Amato R.J., Hernandez-McClain J., Henary H. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Am J Clin Oncol 2008, 31(6):532-538.
46. Lewington V.J. Bone-seeking radionuclides for therapy. J Nucl Med 2005, 46(suppl 1):38S-47S.
47. Storto G., Klain M., Paone G., et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006, 39(1):35-41.
48. Lam M.G., Dahmane A., Stevens W.H., et al. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 2008, 35(4):756-765.
49. Marcus C.S., Saeed S., Mlikotic A., et al. Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin Nucl Med 2002, 27(6):427-430.
50. Lam M.G., de Klerk J.M., Zonnenberg B.A. Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined. J Palliat Med 2009, 12(7):649-651.
51. Tu S.M., Lin S.H., Podoloff D.A., et al. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol 2010, 8(5):341-351.
52. Fuster D., Herranz D., Vidal-Sicart S., et al. Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun 2000, 21(7):623-626.
53. Turner S.L., Gruenewald S., Spry N., et al. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 2001, 84(3):297-302.
54. Ashayeri E., Omogbehin A., Sridhar R., et al. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience. J Natl Med Assoc 2002, 94(8):706-711.
55. Zorga P., Birkenfeld B. Strontium-89 in palliative treatement of painfull bone metastases. Ortop Traumatol Rehabil 2003, 5(3):369-373.
56. Baczyk M., Milecki P., Baczyk E., et al. The effectiveness of strontium 89 in palliative therapy of painful prostate cancer bone metastases. Ortop Traumatol Rehabil 2003, 5(3):364-368.
57. Gunawardana D.H., Lichtenstein M., Better N., et al. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med 2004, 29(2):81-85.
58. Liepe K., Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 2007, 28(8):623-630.
59. Ma Y.B., Yan W.L., Dai J.C., et al. Strontium-89: a desirable therapeutic for bone metastases of prostate cancer [in Chinese]. Zhonghua Nan Ke Xue 2008, 14(9):819-822.
60. Serafini A.N., Houston S.J., Resche I., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998, 16(4):1574-1581.
61. Tian J.H., Zhang J.M., Hou Q.T., et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999, 26(1):2-7.
62. Dolezal J. Systemic radionuclide therapy with samarium-153-EDTMP for painful bone metastases. Nucl Med Rev Cent East Eur 2000, 3(2):161-163.
63. Wang R.F., Zhang C.L., Zhu S.L., et al. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract 2003, 12(2):97-101.
64. Sapienza M.T., Ono C.R., Guimaraes M.I., et al. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy. Rev Hosp Clin Fac Med Sao Paulo 2004, 59(6):321-328.
65. Etchebehere E.C., Pereira Neto C.A., Lima M.C., et al. Treatment of bone pain secondary to metastases using samarium-153-EDTMP. Sao Paulo Med J 2004, 122(5):208-212.
66. Sartor O., Reid R.H., Hoskin P.J., et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004, 63(5):940-945.
67. Tripathi M., Singhal T., Chandrasekhar N., et al. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J Cancer 2006, 43(2):86-92.
68. Dolezal J., Vizda J., Odrazka K. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Urol Int 2007, 78(1):50-57.
69. Ripamonti C., Fagnoni E., Campa T., et al. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer 2007, 15(3):339-342.